Predictors of MTX monotherapy treatment success among patients with RA include low disease activity, normal body weight and ESR levels, and fewer tender joints.

The following is a summary of “High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis,” published in the October 2024 issue ...

A new study published in the Journal of the European Academy of Dermatology and Venereology found that methotrexate (MTX) has ...

will share ex vivo data demonstrating the efficacy of DC-9476 in cells from RA patients that have had an inadequate response to methotrexate (MTX-IR). RA affects approximately 1% of the population ...

Researchers have discovered that methotrexate (MTX) therapy may substantially diminish vaccine-induced CD4 T cell activation resulting in decreased antibody responses in rheumatoid arthritis (RA) ...

Background: DNA damage induced by chemotherapy has duality. It affects the efficacy of chemotherapy and constrains its application. An increasing number of studies have shown that traditional Chinese ...

No writing assistance was utilized in the production of this manuscript. Methotrexate (MTX) is the widely agreed upon first-choice second-line agent to treat juvenile idiopathic arthritis (JIA ...

Pharmacogenetics may be a powerful tool for optimizing methotrexate therapy in patients with RA. The significant variability in clinical response and unpredictable toxicity in patients on MTX ...

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that primarily affects the joints but can also cause damage in other parts of the body. There is currently no cure for RA, but ...

Methotrexate has been the dominant DMARD for the past 15–20 years. As a folate antagonist, methotrexate blocks purine synthesis and, therefore, has cytostatic properties at high dosages ...

Most metabolite levels did not significantly change during cell isolation. Mouse HSCs exhibited increased glycerophospholipids relative to bone marrow cells and methotrexate treatment altered purine ...